Cantor Fitzgerald reiterated its Overweight rating on Solid Biosciences on September 16, 2026. The firm increased its price target to $26.00. Analysts suggest the stock price could more than double ahead of an anticipated clinical update. The firm cited the company’s differentiated approach to treating Duchenne muscular dystrophy.
RBC Capital initiated coverage on the same day with an Outperform rating. The firm set a price target of $18.00. This outlook reflects confidence in the company's gene therapy pipeline for neuromuscular and cardiac diseases.
InvestingPro data shows nine analysts recently revised their earnings estimates upward. These revisions further bolster the current bullish market sentiment.